Detailed Mechanism Funding and Narrative

Years of mechanism: 2014 2015 2016 2017 2018

Details for Mechanism ID: 17623
Country/Region: Rwanda
Year: 2018
Main Partner: Ministry of Health - Rwanda
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $16,011,222 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $542,578
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $542,582
Care: Pediatric Care and Support (PDCS) $542,582
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $810,787
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $678,226
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,635,896
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $10,715,989
Treatment: Pediatric Treatment (PDTX) $542,582
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 112
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 1,290
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 141
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 122
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 75
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 702
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 129
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 33
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 120
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 2,243
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 53
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 30
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 309
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 296
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 33
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 7
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 178
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 275
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 79
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 178
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 275
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 79
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 178
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 199
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 79
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 137
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 160
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 79
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 92
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 16
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 37
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2019 5
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 2,097
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 5,691
GEND_GBV Number of people receiving post-GBV care 2019 7,796
HTS_SELF 2019 70,038
HTS_SELF 15-19, Female, Directly-Assisted 2019 3,502
HTS_SELF 15-19, Female, Unassisted 2019 3,502
HTS_SELF 15-19, Male, Directly-Assisted 2019 3,502
HTS_SELF 15-19, Male, Unassisted 2019 3,502
HTS_SELF 20-24, Female, Directly-Assisted 2019 3,502
HTS_SELF 20-24, Female, Unassisted 2019 4,641
HTS_SELF 20-24, Male, Directly-Assisted 2019 4,616
HTS_SELF 20-24, Male, Unassisted 2019 1,248
HTS_SELF 25-29, Female, Directly-Assisted 2019 701
HTS_SELF 25-29, Female, Unassisted 2019 3,502
HTS_SELF 25-29, Male, Unassisted 2019 3,502
HTS_SELF 30-34, Female, Directly-Assisted 2019 701
HTS_SELF 30-34, Female, Unassisted 2019 3,502
HTS_SELF 30-34, Male, Directly-Assisted 2019 701
HTS_SELF 30-34, Male, Unassisted 2019 3,502
HTS_SELF 35-39, Female, Directly-Assisted 2019 700
HTS_SELF 35-39, Female, Unassisted 2019 3,502
HTS_SELF 35-39, Male, Directly-Assisted 2019 701
HTS_SELF 35-39, Male, Unassisted 2019 3,502
HTS_SELF 40-49, Female, Directly-Assisted 2019 3,502
HTS_SELF 40-49, Female, Unassisted 2019 3,502
HTS_SELF 40-49, Male, Directly-Assisted 2019 3,502
HTS_SELF 40-49, Male, Unassisted 2019 3,502
HTS_SELF 50+, Female, Unassisted 2019 3,502
HTS_SELF Directly-Assisted 2019 25,628
HTS_SELF FSW, Unassisted 2019 14,007
HTS_SELF Unassisted 2019 44,410
HTS_TST <5, Unknown Sex, Negative 2019 1,328
HTS_TST 25-29, Female, Negative 2019 836
HTS_TST 25-29, Female, Negative 2019 5,210
HTS_TST 25-29, Female, Negative 2019 2,380
HTS_TST 25-29, Female, Negative 2019 27,935
HTS_TST 25-29, Female, Negative 2019 18,047
HTS_TST 25-29, Female, Negative 2019 64
HTS_TST 25-29, Female, Negative 2019 17,795
HTS_TST 25-29, Female, Negative 2019 2,845
HTS_TST 25-29, Male, Negative 2019 783
HTS_TST 25-29, Male, Negative 2019 2,978
HTS_TST 25-29, Male, Negative 2019 2,551
HTS_TST 25-29, Male, Negative 2019 18,818
HTS_TST 25-29, Male, Negative 2019 65
HTS_TST 25-29, Male, Negative 2019 18,101
HTS_TST 25-29, Male, Negative 2019 3,983
HTS_TST 25-29, Male, Negative 2019 2,455
HTS_TST 30-34, Female, Negative 2019 767
HTS_TST 30-34, Female, Negative 2019 5,320
HTS_TST 30-34, Female, Negative 2019 2,437
HTS_TST 30-34, Female, Negative 2019 27,935
HTS_TST 30-34, Female, Negative 2019 18,047
HTS_TST 30-34, Female, Negative 2019 64
HTS_TST 30-34, Female, Negative 2019 18,104
HTS_TST 30-34, Female, Negative 2019 5,121
HTS_TST 30-34, Male, Negative 2019 711
HTS_TST 30-34, Male, Negative 2019 2,978
HTS_TST 30-34, Male, Negative 2019 1,703
HTS_TST 30-34, Male, Negative 2019 18,818
HTS_TST 30-34, Male, Negative 2019 64
HTS_TST 30-34, Male, Negative 2019 17,952
HTS_TST 30-34, Male, Negative 2019 4,553
HTS_TST 30-34, Male, Negative 2019 6,384
HTS_TST 35-39, Female, Negative 2019 712
HTS_TST 35-39, Female, Negative 2019 5,320
HTS_TST 35-39, Female, Negative 2019 1,774
HTS_TST 35-39, Female, Negative 2019 27,443
HTS_TST 35-39, Female, Negative 2019 17,395
HTS_TST 35-39, Female, Negative 2019 66
HTS_TST 35-39, Female, Negative 2019 17,658
HTS_TST 35-39, Female, Negative 2019 3,984
HTS_TST 35-39, Male, Negative 2019 692
HTS_TST 35-39, Male, Negative 2019 2,978
HTS_TST 35-39, Male, Negative 2019 1,703
HTS_TST 35-39, Male, Negative 2019 18,063
HTS_TST 35-39, Male, Negative 2019 62
HTS_TST 35-39, Male, Negative 2019 18,584
HTS_TST 35-39, Male, Negative 2019 3,414
HTS_TST 35-39, Male, Negative 2019 4,911
HTS_TST 40-49, Female, Negative 2019 743
HTS_TST 40-49, Female, Negative 2019 5,320
HTS_TST 40-49, Female, Negative 2019 2,296
HTS_TST 40-49, Female, Negative 2019 26,660
HTS_TST 40-49, Female, Negative 2019 17,395
HTS_TST 40-49, Female, Negative 2019 60
HTS_TST 40-49, Female, Negative 2019 18,584
HTS_TST 40-49, Female, Negative 2019 3,984
HTS_TST 40-49, Male, Negative 2019 683
HTS_TST 40-49, Male, Negative 2019 3,063
HTS_TST 40-49, Male, Negative 2019 2,184
HTS_TST 40-49, Male, Negative 2019 13,276
HTS_TST 40-49, Male, Negative 2019 49
HTS_TST 40-49, Male, Negative 2019 17,962
HTS_TST 40-49, Male, Negative 2019 3,414
HTS_TST 40-49, Male, Negative 2019 983
HTS_TST By Key Population: FSW, Negative 2019 6,937
HTS_TST By Key Population: People in prisons and other enclosed settings, Negative 2019 3,217
HTS_TST By Key Population: TG, Negative 2019 6
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 950,002
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2019 2,290
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2019 1,326
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2019 7,024
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2019 2,359
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative 2019 1,068
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2019 620
HTS_TST Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative 2019 4,173
HTS_TST Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative 2019 2,249
HTS_TST Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative 2019 12,696
HTS_TST Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative 2019 2,575
HTS_TST Service Delivery Point (Community) VCT Mod: 50+, Female, Negative 2019 1,471
HTS_TST Service Delivery Point (Community) VCT Mod: 50+, Male, Negative 2019 998
HTS_TST Service Delivery Point (Facility) ANC: 1-9, Negative 2019 5
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 53
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 4,464
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 24,500
HTS_TST Service Delivery Point (Facility) Index: <1, Negative 2019 563
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 3,551
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 1,220
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 1,051
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 1,421
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 1,278
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 1,613
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 918
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 578
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 452
HTS_TST Service Delivery Point (Facility) Inpatient: <1, Negative 2019 558
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 2,632
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 2,393
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 2,389
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 3,599
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 1,247
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 11,799
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 1,635
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 3,939
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 3,305
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 9,571
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 3,772
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 4,907
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 12,198
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 12,299
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 25,717
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 28,351
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 17,327
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 14,994
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 8,576
HTS_TST Service Delivery Point (Facility) TB: <1, Negative 2019 1
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 22
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 29
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 30
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 48
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 43
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 74
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 78
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 125
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 119
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 420
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 3,474
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 4,526
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 10,392
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 15,384
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 27,195
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 31,978
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 30,407
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 13,198
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 13,177
HTS_TST Service Delivery Point (Facility) VMMC: 15-19, Negative 2019 23,563
HTS_TST Service Delivery Point (Facility) VMMC: 20-24, Negative 2019 6,875
HTS_TST Service Delivery Point (Facility) VMMC: 50+, Negative 2019 99
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 1,159
HTS_TST_POS <5, Unknown Sex, Positive 2019 4
HTS_TST_POS 25-29, Female, Positive 2019 306
HTS_TST_POS 25-29, Female, Positive 2019 43
HTS_TST_POS 25-29, Female, Positive 2019 104
HTS_TST_POS 25-29, Female, Positive 2019 189
HTS_TST_POS 25-29, Female, Positive 2019 125
HTS_TST_POS 25-29, Female, Positive 2019 9
HTS_TST_POS 25-29, Female, Positive 2019 260
HTS_TST_POS 25-29, Female, Positive 2019 144
HTS_TST_POS 25-29, Male, Positive 2019 291
HTS_TST_POS 25-29, Male, Positive 2019 25
HTS_TST_POS 25-29, Male, Positive 2019 108
HTS_TST_POS 25-29, Male, Positive 2019 263
HTS_TST_POS 25-29, Male, Positive 2019 9
HTS_TST_POS 25-29, Male, Positive 2019 261
HTS_TST_POS 25-29, Male, Positive 2019 144
HTS_TST_POS 25-29, Male, Positive 2019 18
HTS_TST_POS 30-34, Female, Positive 2019 297
HTS_TST_POS 30-34, Female, Positive 2019 43
HTS_TST_POS 30-34, Female, Positive 2019 67
HTS_TST_POS 30-34, Female, Positive 2019 189
HTS_TST_POS 30-34, Female, Positive 2019 120
HTS_TST_POS 30-34, Female, Positive 2019 9
HTS_TST_POS 30-34, Female, Positive 2019 267
HTS_TST_POS 30-34, Female, Positive 2019 86
HTS_TST_POS 30-34, Male, Positive 2019 271
HTS_TST_POS 30-34, Male, Positive 2019 28
HTS_TST_POS 30-34, Male, Positive 2019 108
HTS_TST_POS 30-34, Male, Positive 2019 263
HTS_TST_POS 30-34, Male, Positive 2019 8
HTS_TST_POS 30-34, Male, Positive 2019 260
HTS_TST_POS 30-34, Male, Positive 2019 144
HTS_TST_POS 30-34, Male, Positive 2019 42
HTS_TST_POS 35-39, Female, Positive 2019 286
HTS_TST_POS 35-39, Female, Positive 2019 44
HTS_TST_POS 35-39, Female, Positive 2019 104
HTS_TST_POS 35-39, Female, Positive 2019 189
HTS_TST_POS 35-39, Female, Positive 2019 119
HTS_TST_POS 35-39, Female, Positive 2019 9
HTS_TST_POS 35-39, Female, Positive 2019 267
HTS_TST_POS 35-39, Female, Positive 2019 144
HTS_TST_POS 35-39, Male, Positive 2019 206
HTS_TST_POS 35-39, Male, Positive 2019 25
HTS_TST_POS 35-39, Male, Positive 2019 84
HTS_TST_POS 35-39, Male, Positive 2019 272
HTS_TST_POS 35-39, Male, Positive 2019 9
HTS_TST_POS 35-39, Male, Positive 2019 261
HTS_TST_POS 35-39, Male, Positive 2019 115
HTS_TST_POS 35-39, Male, Positive 2019 32
HTS_TST_POS 40-49, Female, Positive 2019 212
HTS_TST_POS 40-49, Female, Positive 2019 43
HTS_TST_POS 40-49, Female, Positive 2019 74
HTS_TST_POS 40-49, Female, Positive 2019 210
HTS_TST_POS 40-49, Female, Positive 2019 119
HTS_TST_POS 40-49, Female, Positive 2019 8
HTS_TST_POS 40-49, Female, Positive 2019 267
HTS_TST_POS 40-49, Female, Positive 2019 101
HTS_TST_POS 40-49, Male, Positive 2019 189
HTS_TST_POS 40-49, Male, Positive 2019 16
HTS_TST_POS 40-49, Male, Positive 2019 55
HTS_TST_POS 40-49, Male, Positive 2019 288
HTS_TST_POS 40-49, Male, Positive 2019 8
HTS_TST_POS 40-49, Male, Positive 2019 260
HTS_TST_POS 40-49, Male, Positive 2019 72
HTS_TST_POS 40-49, Male, Positive 2019 7
HTS_TST_POS By Key Population: FSW, Positive 2019 371
HTS_TST_POS By Key Population: People in prisons and other enclosed settings, Positive 2019 38
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive 2019 67
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive 2019 146
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive 2019 90
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive 2019 27
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive 2019 20
HTS_TST_POS Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive 2019 101
HTS_TST_POS Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive 2019 20
HTS_TST_POS Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive 2019 232
HTS_TST_POS Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive 2019 26
HTS_TST_POS Service Delivery Point (Community) VCT Mod: 50+, Female, Positive 2019 34
HTS_TST_POS Service Delivery Point (Community) VCT Mod: 50+, Male, Positive 2019 72
HTS_TST_POS Service Delivery Point (Facility) ANC: 10-14, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 41
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 176
HTS_TST_POS Service Delivery Point (Facility) Index: <1, Positive 2019 40
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 49
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 101
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 323
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 243
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 145
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 132
HTS_TST_POS Service Delivery Point (Facility) Inpatient: <1, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 23
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 58
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 40
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 50
HTS_TST_POS Service Delivery Point (Facility) Other PITC: <1, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 25
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 74
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 38
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 285
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 152
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 152
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 181
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 40
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 6
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) VCT: <1, Positive 2019 10
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 18
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 135
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 432
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 155
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 255
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 259
PMTCT_ART Already on ART at beginning of current pregnancy 2019 2,482
PMTCT_ART New on ART 2019 705
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 3,187
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 103,083
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 3,037
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 153
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 3,190
PMTCT_EID Sum of Infant Age disaggregates 2019 3,190
PMTCT_STAT 25-29, Female 2019 18,281
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 550
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 17,592
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 119
PMTCT_STAT 30-34, Female 2019 18,134
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 550
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 17,449
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 111
PMTCT_STAT 35-39, Female 2019 18,131
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 550
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 17,449
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 110
PMTCT_STAT 40-49, Female 2019 18,004
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 550
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 17,321
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 110
PMTCT_STAT By Age (Numerator): 10-14 2019 17
PMTCT_STAT By Age (Numerator): 15-19 2019 4,557
PMTCT_STAT By Age (Numerator): 20-24 2019 25,729
PMTCT_STAT By Age (Numerator): 50+ 2019 4
PMTCT_STAT By Number of known positives: 10-14 2019 2
PMTCT_STAT By Number of known positives: 15-19 2019 51
PMTCT_STAT By Number of known positives: 20-24 2019 249
PMTCT_STAT By Number of new negative: 10-14 2019 15
PMTCT_STAT By Number of new negative: 15-19 2019 4,464
PMTCT_STAT By Number of new negative: 20-24 2019 25,329
PMTCT_STAT By Number of new negative: 50+ 2019 4
PMTCT_STAT By Number of new positives: 10-14 2019 1
PMTCT_STAT By Number of new positives: 15-19 2019 43
PMTCT_STAT By Number of new positives: 20-24 2019 164
PMTCT_STAT Number of new ANC and L&D clients 2019 104,134
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 103,083
PMTCT_STAT_den 25-29, Female 2019 18,791
PMTCT_STAT_den 30-34, Female 2019 17,929
PMTCT_STAT_den 35-39, Female 2019 17,929
PMTCT_STAT_den 40-49, Female 2019 17,659
PMTCT_STAT_den By Age (Denominator): <15-19 2019 5,098
PMTCT_STAT_den By Age (Denominator): 10-14 2019 72
PMTCT_STAT_den By Age (Denominator): 20-24 2019 26,656
PrEP_NEW 25-29, Female 2019 77
PrEP_NEW 25-29, Male 2019 21
PrEP_NEW 30-34, Female 2019 43
PrEP_NEW 30-34, Male 2019 86
PrEP_NEW 35-39, Female 2019 43
PrEP_NEW 35-39, Male 2019 43
PrEP_NEW 40-49, Female 2019 21
PrEP_NEW Female 15-19 2019 21
PrEP_NEW Female 20-24 2019 51
PrEP_NEW Male 20-24 2019 21
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 428
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 4
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 166
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 4
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 250
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 417
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 50
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 511
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 73
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 958
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 1,546
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 1,546
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 45
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 501
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 62
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 952
TX_CURR 25-29, Female, Positive 2019 10,846
TX_CURR 25-29, Female, Positive 2019 1,925
TX_CURR 25-29, Male, Positive 2019 5,681
TX_CURR 25-29, Male, Positive 2019 958
TX_CURR 30-34, Female, Positive 2019 10,846
TX_CURR 30-34, Female, Positive 2019 1,925
TX_CURR 30-34, Male, Positive 2019 5,681
TX_CURR 30-34, Male, Positive 2019 958
TX_CURR 35-39, Female, Positive 2019 10,846
TX_CURR 35-39, Female, Positive 2019 1,925
TX_CURR 35-39, Male, Positive 2019 5,681
TX_CURR 35-39, Male, Positive 2019 958
TX_CURR 40-49, Female, Positive 2019 10,846
TX_CURR 40-49, Female, Positive 2019 1,925
TX_CURR 40-49, Male, Positive 2019 5,681
TX_CURR 40-49, Male, Positive 2019 958
TX_CURR Age/Sex: <1 2019 32
TX_CURR Age/Sex: <1-9 2019 1,965
TX_CURR Age/Sex: 1-9 2019 211
TX_CURR Age/Sex: 10-14 Female 2019 1,407
TX_CURR Age/Sex: 10-14 Female 2019 139
TX_CURR Age/Sex: 10-14 Male 2019 1,384
TX_CURR Age/Sex: 10-14 Male 2019 142
TX_CURR Age/Sex: 15-19 Female 2019 2,030
TX_CURR Age/Sex: 15-19 Female 2019 283
TX_CURR Age/Sex: 15-19 Male 2019 1,553
TX_CURR Age/Sex: 15-19 Male 2019 254
TX_CURR Age/Sex: 20-24 Female 2019 4,616
TX_CURR Age/Sex: 20-24 Female 2019 687
TX_CURR Age/Sex: 20-24 Male 2019 1,869
TX_CURR Age/Sex: 20-24 Male 2019 300
TX_CURR Age/Sex: 50+ Female 2019 13,097
TX_CURR Age/Sex: 50+ Female 2019 1,773
TX_CURR Age/Sex: 50+ Male 2019 11,275
TX_CURR Age/Sex: 50+ Male 2019 1,601
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 105,429
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 16,997
TX_CURR Sum of age/sex disaggregates 2019 3,583
TX_CURR Sum of Age/Sex disaggregations 2019 537
TX_NEW 25-29, Female, Positive 2019 1,192
TX_NEW 25-29, Female, Positive 2019 25
TX_NEW 25-29, Male, Positive 2019 944
TX_NEW 25-29, Male, Positive 2019 22
TX_NEW 30-34, Female, Positive 2019 1,192
TX_NEW 30-34, Female, Positive 2019 24
TX_NEW 30-34, Male, Positive 2019 944
TX_NEW 30-34, Male, Positive 2019 21
TX_NEW 35-39, Female, Positive 2019 1,192
TX_NEW 35-39, Female, Positive 2019 21
TX_NEW 35-39, Male, Positive 2019 940
TX_NEW 35-39, Male, Positive 2019 20
TX_NEW 40-49, Female, Positive 2019 1,192
TX_NEW 40-49, Female, Positive 2019 22
TX_NEW 40-49, Male, Positive 2019 940
TX_NEW 40-49, Male, Positive 2019 20
TX_NEW Breastfeeding status 2019 233
TX_NEW By Age/Sex: <1 2019 50
TX_NEW By Age/Sex: <1 2019 1
TX_NEW By Age/Sex: 1-9 2019 89
TX_NEW By Age/Sex: 1-9 2019 3
TX_NEW By Age/Sex: 10-14 Female 2019 185
TX_NEW By Age/Sex: 10-14 Female 2019 6
TX_NEW By Age/Sex: 10-14 Male 2019 65
TX_NEW By Age/Sex: 15-19 Female 2019 517
TX_NEW By Age/Sex: 15-19 Female 2019 8
TX_NEW By Age/Sex: 15-19 Male 2019 142
TX_NEW By Age/Sex: 15-19 Male 2019 1
TX_NEW By Age/Sex: 20-24 Female 2019 1,467
TX_NEW By Age/Sex: 20-24 Female 2019 44
TX_NEW By Age/Sex: 20-24 Male 2019 535
TX_NEW By Age/Sex: 20-24 Male 2019 6
TX_NEW By Age/Sex: 50+ Female 2019 688
TX_NEW By Age/Sex: 50+ Female 2019 3
TX_NEW By Age/Sex: 50+ Male 2019 697
TX_NEW By Age/Sex: 50+ Male 2019 2
TX_NEW By Key populations: People who inject drugs (PWID) 2019 4
TX_NEW FSW 2019 152
TX_NEW FSW 2019 50
TX_NEW MSM 2019 4
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 12,876
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 249
TX_NEW People in prisons and other enclosed settings 2019 184
TX_NEW Pregnancy status 2019 1,180
TX_NEW Pregnancy status 2019 18
TX_NEW Sum of Age/Sex disaggregates 2019 4,296
TX_NEW Sum of Age/Sex disaggregates 2019 70
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 92,531
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 18,491
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 4,633
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 18,475
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 4,631
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 18,487
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 4,623
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 18,527
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 4,608
TX_PVLS_den Denominator: Indication: Routine 2019 74,024
TX_PVLS_den Denominator: Indication: Targeted 2019 18,505
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 164
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 170
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 7,468
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 4,440
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 12,251
TX_RET Numerator by Status: Breastfeeding 2019 60
TX_RET Numerator by Status: Pregnant 2019 718
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 12,888
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 171
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 175
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 7,820
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 4,698
TX_RET_den Denominator by Status: Breastfeeding 2019 73
TX_RET_den Denominator by Status: Pregnant 2019 808
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 121,758
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 2,893
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 2,774
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 73,489
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 42,605
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 836
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 997
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 1,827
VMMC_CIRC 30-34, Male 2019 1,966
VMMC_CIRC 35-39, Male 2019 1,477
VMMC_CIRC 40-49, Male 2019 241
VMMC_CIRC By Age: 10-14 2019 1,232
VMMC_CIRC By Age: 15-19 2019 31,758
VMMC_CIRC By Age: 20-24 2019 8,844
VMMC_CIRC By Age: 25-29 2019 3,678
VMMC_CIRC By circumcision technique: Device-based VMMC 2019 14,756
VMMC_CIRC By circumcision technique: Surgical VMMC 2019 34,437
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2019 49,194
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2019 45,512
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2019 41,834
Cross Cutting Budget Categories and Known Amounts Total: $7,849,266
Key Populations: MSM and TG $25,159
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Key Populations: Sex Workers $35,222
Training of health workers and community outreach workers
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Monitoring and evaluation of SW programs
Gender: Gender Based Violence (GBV) $60,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Implementation
Capacity building
Human Resources for Health $7,724,810
Food and Nutrition: Policy, Tools, and Service Delivery $4,075